De-adoption and its 43 related terms: Harmonizing low-value care terminology

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Gnjidic, Danijela ^a   Elshaug, Adam G ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c Lown Cardiovascular Group   (United States)

Author keywords

De adoption; Harmful; Ineffective; Low value care; Medical interventions

Indexed keywords

NEUROLEPTIC AGENT;

AUSTRALIA; CANADA; CLINICAL PRACTICE; DECISION MAKING; DEMENTIA; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HUMAN; MEDICAL PRACTICE; NOMENCLATURE; NOTE; PREVALENCE; UNITED KINGDOM; UNITED STATES; STANDARDS; TOTAL QUALITY MANAGEMENT;

HUMANS; PRACTICE PATTERNS, PHYSICIANS'; QUALITY IMPROVEMENT;

EID: 84945194816     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0511-4     Document Type: Note

References (17)

1. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? BMJ. 2011;343:d4519.
2. Elshaug AG, Hiller JE, Tunis SR, Moss JR. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy. 2007;4:23.
3. Niven DJ, Mrklas KJ, Holodinsky JK, Straus SE, Hemmelgarn BR, Jeffs LP, et al. Towards understanding the de-adoption of low-value clinical practices: a scoping review. BMC Med. 2015;13:255.
4. Wirtz V, Cribb A, Barber N. Reimbursement decisions in health policy-extending our understanding of the elements of decision-making. Health Policy. 2005;73:330-8.
5. MacKean G, Noseworthy T, Elshaug AG, Leggett L, Littlejohns P, Berezanski J, et al. Health technology reassessment: the art of the possible. Int J Technol Assess Health Care. 2013;29:418-23.
6. Morgan DJ, Brownlee S, Leppin AL, Kressin N, Dhruva SS, Levin L, et al. Setting a research agenda for medical overuse. BMJ. 2015;351:h4534.
7. Elshaug AG, McWilliams JM, Landon BE. The value of low-value lists. JAMA. 2013;309:775-6.
8. Levinson W. Searching for effective innovations I: reducing low-value care. Webinar. Washington: Academy Health; 2015. http://www.academyhealth.org/Events/events.cfm?ItemNumber=16876. Accessed 10 Jan 2015.
9. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827-34.
10. Gnjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. BMJ. 2014;349:g7013.
11. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33:905-24.
12. Paprica PA, Culyer AJ, Elshaug AG, Peffer J, Sandoval GA. From talk to action: policy stakeholders, appropriateness, and selective disinvestment. Int J Technol Assess Health Care. 2015. Ahead of print.
13. Wilson MG, Ellen ME, Lavis JN, Grimshaw JM, Moat KA, Shemer J, et al. Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis. Syst Rev. 2014;3:143.
14. OECD. Geographic variations in health care: what do we know and what can be done to improve health system performance? Focus on Health. Paris: OECD; 2014. http://www.oecd.org/els/health-systems/FOCUS-on-Geographic-Variations-in-Health-Care.pdf.
15. Bhatia RS, Levinson W, Shortt S, Pendrith C, Fric-Shamji E, Kallewaard M, et al. Measuring the effect of Choosing Wisely: an integrated framework to assess campaign impact on low-value care. BMJ Qual Saf. 2015;24:523-31.
16. Haas M, Hall J, Viney R, Gallego G. Breaking up is hard to do: why disinvestment in medical technology is harder than investment. Aust Health Rev. 2012;36:148-52.
17. Sheingold S, Sheingold BH. Medical technology in the U.S. healthcare system: is this the road to Abilene? World Med Health Policy. 2010;2:Article 5.